<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710239</url>
  </required_header>
  <id_info>
    <org_study_id>5209</org_study_id>
    <nct_id>NCT03710239</nct_id>
  </id_info>
  <brief_title>OPIOID Study - Pain With Osmotic Dilators</brief_title>
  <acronym>OPIOID</acronym>
  <official_title>OPIOID Study: Opioid Use and Pain After Insertion of Osmotic Dilators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of pain levels and pain medications utilized following insertion of two different
      types of osmotic dilators.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled trial to assess and compare pain levels and pain medication
      needs following placement of Laminaria versus Dilapan-S for cervical preparation prior to
      second-trimester dilation and evacuation (D&amp;E) procedures. Pain levels and medication usage
      will also be assessed following the D&amp;E procedure itself, up to 7 days after the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2, 2018</start_date>
  <completion_date type="Actual">March 11, 2020</completion_date>
  <primary_completion_date type="Actual">March 11, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to receive one of two existing dilator times, with the remainder of care and study procedures being identical.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will not know what type of dilator they have been assigned, however the medical care team (including investigators) will be aware.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum pain above baseline following Laminaria versus Dilapan-S placement</measure>
    <time_frame>First 24 hours after dilator placement</time_frame>
    <description>Timed surveys measuring pain on Numeric Rating Scale (0-10), administered approximately 24 hours after dilator placement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum pain above baseline following Laminaria versus Dilapan-S placement</measure>
    <time_frame>First 24 hours after dilator placement</time_frame>
    <description>Timing of maximum Numeric Rating Scale (0-10) pain difference among measurements approximately 24 hours after dilator placement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain medication use after Laminaria versus Dilapan-S placement</measure>
    <time_frame>First 24 hours after dilator placement</time_frame>
    <description>Timed surveys of pain medication usage at 2 hours, 4 hours, 8 hours, and approximately 24 hours after dilator placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum pain increase over baseline following D&amp;E procedure</measure>
    <time_frame>First week after D&amp;E</time_frame>
    <description>Timed surveys measuring pain on Numeric Rating Scale (0-10), administered at 1 hour, 4 hours, 24 hours, 48 hours, and 1 week after D&amp;E procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain medication use after D&amp;E</measure>
    <time_frame>First week after D&amp;E</time_frame>
    <description>Timed surveys of pain medication usage, administered at 4 hours, 24 hours, 48 hours, and 1 week after D&amp;E procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Abortion in Second Trimester</condition>
  <arm_group>
    <arm_group_label>Dilapan-S</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Synthetic osmotic dilator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laminaria</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Seaweed-based osmotic dilator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dilapan-S</intervention_name>
    <description>Synthetic osmotic dilator</description>
    <arm_group_label>Dilapan-S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laminaria</intervention_name>
    <description>Seaweed-based osmotic dilator</description>
    <arm_group_label>Laminaria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  scheduled D&amp;E for 15+0 to 23+6 wga

          -  ability to speak and read in English

          -  ownership of smartphone with internet access and data plan

        Exclusion Criteria:

        - chronic pain, fibromyalgia, active pelvic infection, inability to take NSAIDS, current
        use of narcotics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Albany Medical Center Obstetrics and Gynecology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 14, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

